Plus Therapeutics Surges to 369th in Daily Rankings with $25.9 Million Turnover

On June 25, 2025, Plus Therapeutics (PSTV) saw a significant surge in trading volume, with a total turnover of $25.9 million, marking an 863.29% increase from the previous day. This substantial rise in trading volume placed Plus Therapeutics at the 369th position in the daily stock market rankings. The stock price of Plus Therapeutics also experienced a notable increase, rising by 68.45% over the past two days, with a cumulative gain of 70.92%.

Plus Therapeutics is scheduled to provide a business update and host a conference call on Thursday, June 26, 2025, at 9:00 A.M. ET. This event is expected to offer insights into the company's recent developments and future strategies, potentially influencing investor sentiment and stock performance.

Plus Therapeutics has recently received FDA clearance for its Investigational New Drug Application using REYOBIQ™ for the treatment of childhood brain cancer. This clearance is a significant milestone for the company, as it paves the way for further clinical trials and potential market approval. The positive news has generated considerable momentum for the stock, with investors closely monitoring the company's progress in this critical area of research.

Investors have shown strong interest in Plus Therapeutics, with some taking substantial positions in the stock. The company's recent developments and upcoming conference call have contributed to a sense of optimism among investors, who are eager to see how these advancements will translate into future growth and profitability.